1. A Saccharomyces boulardii-derived antioxidant protein, thioredoxin, ameliorates intestinal inflammation through transactivating epidermal growth factor receptor
- Author
-
Xiali Qin, Qing Zhao, Qianjing Zhao, Lijiao Yang, Wanyu Li, Jingyi Wu, Tianyu Liu, Weilong Zhong, Kui Jiang, Wentian Liu, Bangmao Wang, Sinan Wang, and Hailong Cao
- Subjects
Saccharomyces boulardii ,Colitis ,Intestinal barrier ,Thioredoxin ,Oxidative stress ,Epidermal growth factor receptor ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Saccharomyces boulardii (Sb) is a probiotic yeast for the treatment of gastrointestinal disorders, including inflammatory bowel disease (IBD). Little is known about the modulatory capacity of the Sb in IBD. Here, we found that oral gavage of Sb supernatant (SbS) alleviated gut inflammation, protected the intestinal barrier, and reversed DSS-induced down-regulated activation of epidermal growth factor receptor (EGFR) in colitis. Mass spectrum analysis showed that thioredoxin (Trx) is one of the critical secreted soluble proteins participating in EGFR activation detected in SbS. Trx exerted an array of significant effects on anti-inflammatory activity, including alleviating inflammation, protecting gut barrier, suppressing apoptosis, as well as reducing oxidative stress. Mechanistically, Trx promoted EGFR ligand gene expression and transactivated EGFR in a concentration-dependent manner. EGFR kinase inhibitor could block Trx-mediated preventive effects of intestinal epithelial injury. Our data suggested that Sb-derived soluble protein Trx could serve as a potential prophylactic, as a novel postbiotic against colitis, which provides a new strategy for the precision prevention and treatment of IBD.
- Published
- 2024
- Full Text
- View/download PDF